CYTK drops violently
Cytokinetics showed sharply higher MYQORZO revenue and maintained expense guidance, but with no EPS consensus supplied the stock fell violently as the market weighed the wider net loss and launch spending.
Previous verdicts for CYTK
- AI Search: Insider Share Sale Weighs Modestly on Cytokinetics Stock — 2026-11-04
- AI Search: Cytokinetics Slips Modestly After Sell Rating Downgrade — 2026-10-23
- AI Search: William Blair's Higher Target Gives Cytokinetics a Bullish Nudge — 2026-10-20
- AI Search: Cytokinetics Rises as UBS Maintains Buy Despite Target Trim — 2026-10-14
- AI Search: Cytokinetics Slips Slightly as Investors Weigh Aficamten Trial Safety Data — 2026-10-13
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works